Key result
Albuminuria is associated with the progression of chronic kidney disease and the occurrence of cardiovascular events in patients with and without diabetes.
Why the study?
How exactly microalbuminuria is linked to cardiovascular risk remains unclear.
Albuminuria is a key prognostic marker for chronic kidney disease progression and cardiovascular events, and its reduction should be a therapeutic target.
Albuminuria aids prognostic assessment in CKD with or without diabetes; leaves open whether targeting it improves outcomes.
Albuminuria is associated with the progression of chronic kidney disease and the occurrence of cardiovascular events in patients with and without diabetes. The evolution of albuminuria appears to be associated with patient's prognosis. How exactly microalbuminuria is linked to cardiovascular risk remains unclear. This association is probably explained by endothelial dysfunction or chronic low-grade inflammation. Albuminuria/creatininuria ratio allows reduction of potential errors in urine collection. In France, the recommendations for the monitoring of albuminuria depend on the cause of albuminuria. An increase in urinary albumin excretion could signify the need for an intensive multifactorial intervention strategy and albuminuria is a relevant biological marker to monitor therapeutic effectiveness, since a reduction of albuminuria in patients, irrespective of their diabetic status, predicts reduction of cardiovascular risk.
No takes yet. Share an insight, caveat, or question.
Souweine et al. (2019) conducted a review in Chronic kidney disease, diabetes, cardiovascular risk. Albuminuria was evaluated. Albuminuria is associated with the progression of chronic kidney disease and the occurrence of cardiovascular events in patients with and without diabetes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: